GlassScriptPhysician profile
Joshua Andrew Smith
NPI 1174055214
$4,472.65
in general payments reported to CMS, 2019-2025
23 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 77% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $377 · 2023: $1,051 · 2024: $1,294 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085 · Education: $9.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,085.46 |
| Education | $9.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,565.56 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $632.16 | 2022-2025 | |
| Neurelis, INC. | $568.08 | 2022-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $338.04 | 2023-2025 | Fycompa |
| Acadia Pharmaceuticals INC | $287.02 | 2023-2025 | Daybue |
| Aucta Pharmaceuticals, INC. | $180.35 | 2024-2025 | Motpoly Xr |
| Supernus Pharmaceuticals, INC. | $160.42 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $151.14 | 2022-2025 | Azstarys |
| Immedica Pharma US, INC. | $108.61 | 2023-2025 | Ztalmy |
| Sumitomo Pharma America, INC. | $106.41 | 2023-2024 | Aptiom |
| Aquestive Therapeutics, INC. | $64.61 | 2022-2024 | |
| Pyros Pharmaceuticals, INC. | $41.29 | 2024 | Vigpoder |
| Sk Life Science, INC. | $37.45 | 2025 | |
| Eisai INC. | $31.68 | 2023 | |
| Intrabio INC | $31.48 | 2025 | Aqneursa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $31.14 | 2024 | Elevidys |
| Abbvie INC. | $28.59 | 2025 | |
| Itf Therapeutics LLC | $22.48 | 2025 | |
| Sunovion Pharmaceuticals INC. | $20.11 | 2022 | |
| Tris Pharma INC | $17.48 | 2025 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $17.09 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.32 | 2025 | Zonisade |
| Collegium Pharmaceutical, INC. | $15.14 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.